Title: Sensitivity relationship of ERCC1 and XRCC1 genetic polymorphism on response of platinum-based chemotherapy in advanced NSCLC
Abstract: Objective To investigate the relationship of genetic polymorphisms in excision repair cross-complementation group 1(ERCC1) 118 and X-ray repair cross-complementing group 1(XRCC1) 194 and the response to platinum-based chemotherapy in non-small cell lung cancer(NSCLC).Methods A total of 149 advanced NSCLC patients who received platinum-based chemotherapy were analyzed in this study.Their DNA of peripheral blood leukocytes was extracted and ERCC1 118C/T,XRCC1 Arg194Trp genotypes were detected by the PCR-RFLP method in 149 patients with advanced NSCLC who received platinum-based chemotherapy.The relationship of ERCC1 and XRCC1 polymorphism with chemotherapy sensitivity was analyzed.Results After two chemotherapy cycles,the overall response rate in all patients was 32.9%.The patients with the ERCC1 118 C/T+T/T polymorphisms were at least 3-folds more sensitive to the chemotherapy as those with the C/C genotype(49.1% vs 23.4%,OR=3.156,95%CI,1.548~6.334,P=0.001).The response rate to the chemotherapy among the patients with XRCC1 194Trp allele was significantly higher than that among the patients with Arg/Arg genotype(41.3% vs 23.2%,OR=2.326,95%CI,1.138~4.753,P=0.019).A cooperateive action effect between ERCC1 118 and XRCC1 194 polymorphisms was also found.The response rate to the therapy among the patients with 118 T allele and 194 Trp allele was significantly higher than that among the patients with ERCC1 118 C/C and XRCC1 194Arg/Arg genotype(66.7% vs 17.1%,OR=9.714,95%CI,3.104~30.406,P0.001).Conclusions In comparison with the single genepolymorphism,the combined effect of ERCC1 and XRCC1 polymorphisms is more valuable in predicting the responses of the platinum-based chemotherapy.The polymorphisms of the ERCC1 and XRCC1 are associated with the clinical response to platinum-based chemotherapy in NSCLC,suggesting that the ERCC1 and XRCC1 genotypes could be used to predict the advanced NSCLC patients with better responses to platinum-based chemotherapy.
Publication Year: 2012
Publication Date: 2012-01-01
Language: en
Type: article
Access and Citation
Cited By Count: 3
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot